Evaluating the Feasibility of Screening Relatives of Patients Affected by Nonsyndromic Thoracic Aortic Diseases: The REST Study

Riccardo Giuseppe Abbasciano, Giovanni Mariscalco, Julian Barwell, Gareth Owens, Mustafa Zakkar, Lathishia Joel-David, Suraj Pathak, Adewale Adebayo, Nora Shannon, Rebecca Louise Haines, Hardeep Aujla, Bryony Eagle-Hemming, Tracy Kumar, Florence Lai, Marcin Wozniak, Gavin Murphy, Riccardo Giuseppe Abbasciano, Giovanni Mariscalco, Julian Barwell, Gareth Owens, Mustafa Zakkar, Lathishia Joel-David, Suraj Pathak, Adewale Adebayo, Nora Shannon, Rebecca Louise Haines, Hardeep Aujla, Bryony Eagle-Hemming, Tracy Kumar, Florence Lai, Marcin Wozniak, Gavin Murphy

Abstract

Background Diseases of the thoracic aorta are characterized by a familial etiology in up to 30% of the cases. Nonsyndromic thoracic aorta diseases (NS-TADs) lack overt clinical signs and systemic features, which hinder early detection and prompt surgical intervention. We hypothesize that tailored genetic testing and imaging of first-degree and second-degree relatives of patients affected by NS-TADs may enable early diagnosis and allow appropriate surveillance or intervention. Methods and Results We conducted a feasibility study involving probands affected by familial or sporadic NS-TADs who had undergone surgery, which also offered screening to their relatives. Each participant underwent a combined imaging (echocardiogram and magnetic resonance imaging) and genetic (whole exome sequencing) evaluation, together with physical examination and psychological assessment. The study population included 16 probands (8 sporadic, 8 familial) and 54 relatives (41 first-degree and 13 second-degree relatives) with median age 48 years (range: 18-85 years). No syndromic physical features were observed. Imaging revealed mild-to-moderate aortic dilation in 24% of relatives. A genetic variant of uncertain significance was identified in 3 families. Imaging, further phenotyping, or a form of secondary prevention was indicated in 68% of the relatives in the familial group and 54% in the sporadic group. No participants fulfilled criteria for aortic surgery. No differences between baseline and 3-month follow-up scores for depression, anxiety, and self-reported quality of life were observed. Conclusions In NS-TADs, imaging tests, genetic counseling, and family screening yielded positive results in up to 1 out of 4 screened relatives, including those in the sporadic NS-TAD group. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT03861741.

Keywords: familial thoracic aortic aneurysm and dissection; genetic screening; whole exome sequencing.

Figures

Figure 1. Consolidated Standards of Reporting Trials…
Figure 1. Consolidated Standards of Reporting Trials diagram for study recruitment and follow‐up.
In 2 relatives a sufficient amount of blood could not be collected because of poor peripheral vasculature; the proband tested negative for variants in these cases. FDR indicates first‐degree relative; MRI, magnetic resonance imaging; SDR, second‐degree relative; and TTE, transthoracic echocardiogram.
Figure 2. Summary of the findings related…
Figure 2. Summary of the findings related to the imaging study procedures.
Fifty‐four participants underwent transthoracic echocardiogram as part of the study procedures, and 43 had both echocardiogram and MRI. Thirteen imaging diagnoses of mild‐to‐moderate aortic dilatation were reached. FDR indicates first‐degree relative; MRI, magnetic resonance imaging; SDR, second‐degree relative; and TTE, transthoracic echocardiogram.
Figure 3. Flow chart describing the variant…
Figure 3. Flow chart describing the variant filtering and evaluation process.
The complete list was reduced by filtering for (in order) type of variant (synonymous vs nonsynonymous), rarity in gnomAD (less vs more than 5% of the general population), predicted impact of the mutation (high/moderate vs low impact), classification in ClinVar (pathogenic/likely pathogenic/uncertain significance vs benign/likely benign) and evaluated finally according to the American College of Medical Genetics and Genomics criteria. ACMG indicates American College of Medical Genetics and Genomics; VUS, variant of uncertain significance; and VUS‐LP‐P, variant of uncertain significance likely pathogenic‐pathogenic.
Figure 4. Summary of the findings related…
Figure 4. Summary of the findings related to the genetic test study procedures.
After ACMG evaluation and multidisciplinary team discussion, 3 participants were rephenotyped by a clinical geneticist where deep phenotyping might alter variant classification. FDR indicates first‐degree relative; SDR, second degree relative; and VUS, variant of uncertain significance.
Figure 5. Summary of the overall study…
Figure 5. Summary of the overall study findings.
Sixteen families of patients with nonsyndromic thoracic aortic disease (NS‐TAD) were involved in a feasibility study to evaluate a combined approach to screening for aortopathy. Results showed an aortic dilatation in 24% and a genotype that required rephenotyping in 15% of the relatives respectively. Thirteen participants required imaging follow‐up, and 3 families a further clinical genetics reevaluation. FDR indicates first‐degree relative; MRI, magnetic resonance imaging; SDR, second degree relative; TTE, transthoracic echocardiogram; and VUS, variant of uncertain significance.

References

    1. Verstraeten A, Luyckx I, Loeys B. Aetiology and management of hereditary aortopathy. Nat Rev Cardiol. 2017;14:197–208. doi: 10.1038/nrcardio.2016.211
    1. Sampson UK, Norman PE, Fowkes FG, Aboyans V, Song Y, Harrell FE Jr, Forouzanfar MH, Naghavi M, Denenberg JO, McDermott MM, Criqui MH. Global and regional burden of aortic dissection and aneurysms: mortality trends in 21 world regions. Glob Heart. 1990;2014:171–180.
    1. Tanaka Y, Sakata K, Sakurai Y, Yoshimuta T, Morishita Y, Nara S, Takahashi I, Hirokami M, Yamagishi M. Prevalence of type A acute aortic dissection in patients with out‐of‐hospital cardiopulmonary arrest. Am J Cardiol. 2016;117:1826–1830. doi: 10.1016/j.amjcard.2016.03.015
    1. Erbel RAV, Boileau C, Bossone E, Bartolomeo RD, Eggebrecht H, et al. ESC Guidelines on the diagnosis and treatment of aortic diseases: document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC). Eur Heart J. 2014;35:2873–2926. doi: 10.1093/eurheartj/ehu281
    1. Hiratzka LFBG, Beckman JA, Bersin RM. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with Thoracic Aortic Disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. Circulation. 2010;121:e266–e369.doi: 10.1161/CIR.0b013e3181d4739e
    1. Fletcher AJ, Syed MBJ, Aitman TJ, Newby DE, Walker NL. Inherited thoracic aortic disease: new insights and translational targets. Circulation. 2002;141:1570–1587. doi: 10.1161/CIRCULATIONAHA.119.043756
    1. Faggion Vinholo T, Zafar MA, Ziganshin BA, Elefteriades JA. Nonsyndromic thoracic aortic aneurysms and dissections—is screening possible? Semin Thorac Cardiovasc Surg. 2019;31:628–634. doi: 10.1053/j.semtcvs.2019.05.035
    1. Mariscalco G, Debiec R, Elefteriades JA, Samani NJ, Murphy GJ. Systematic review of studies that have evaluated screening tests in relatives of patients affected by nonsyndromic thoracic aortic disease. J Am Heart Assoc. 2018;7:e009302. doi: 10.1161/JAHA.118.009302
    1. Abbasciano RG, Barwell J, Sayers R, Bown M, Milewicz D, Cooper G, Mariscalco G, Wheeldon N, Fowler C, Owens G, et al. Report of a Delphi exercise to inform the design of a research programme on screening for thoracic aortic disease. Trials. 2020;21:656. doi: 10.1186/s13063-020-04562-1
    1. Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA, et al. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. BMJ. 2016;355:i5239. doi: 10.1136/bmj.i5239
    1. Jenkinson C, Coulter A, Wright L. Short form 36 (SF36) health survey questionnaire: normative data for adults of working age. BMJ. 1993;306:1437–1440. doi: 10.1136/bmj.306.6890.1437
    1. Kroenke K, Spitzer RL, Williams JBW. The PHQ‐9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16:606–613. doi: 10.1046/j.1525-1497.2001.016009606.x
    1. Spitzer RL, Kroenke K, Williams JBW, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD‐7. Arch Intern Med. 2006;166:1092–1097. doi: 10.1001/archinte.166.10.1092
    1. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18:1440–1463. doi: 10.1016/j.echo.2005.10.005
    1. Goldstein SA, Evangelista A, Abbara S, Arai A, Asch FM, Badano LP, Bolen MA, Connolly HM, Cuéllar‐Calàbria H, Czerny M, et al. Multimodality imaging of diseases of the thoracic aorta in adults: from the American Society of Echocardiography and the European Association of Cardiovascular Imaging: endorsed by the Society of Cardiovascular Computed Tomography and Society for Cardiovascular Magnetic Resonance. J Am Soc Echocardiogr. 2015;28:119–182. doi: 10.1016/j.echo.2014.11.015
    1. Devereux RB, de Simone G, Arnett DK, Best LG, Boerwinkle E, Howard BV, Kitzman D, Lee ET, Mosley TH, Weder A, et al. Normal limits in relation to age, body size and gender of two‐dimensional echocardiographic aortic root dimensions in persons ≥15 years of age. Am J Cardiol. 2012;110:1189–1194. doi: 10.1016/j.amjcard.2012.05.063
    1. Evangelista A, Flachskampf FA, Erbel R, Antonini‐Canterin F, Vlachopoulos C, Rocchi G, Sicari R, Nihoyannopoulos P, Zamorano J, Pepi M, et al. Echocardiography in aortic diseases: EAE recommendations for clinical practice. Eur J Echocardiogr. 2010;11:645–658. doi: 10.1093/ejechocard/jeq056
    1. Turkbey EB, Jain A, Johnson C, Redheuil A, Arai AE, Gomes AS, Carr J, Hundley WG, Teixido‐Tura G, Eng J, et al. Determinants and normal values of ascending aortic diameter by age, gender, and race/ethnicity in the Multi‐Ethnic Study of Atherosclerosis (MESA). J Magn Reson Imaging. 2014;39:360–368. doi: 10.1002/jmri.24183
    1. Fung KBL, Aung N, Hann E, Paiva J, Lukaschuk E, et al. Reference values for aortic distensibility derived from UK Biobank cardiovascular magnetic resonance (CMR) imaging cohort. Eur Heart J ‐ Cardiovasc Imaging. 2019;20(Supplement_2):jez114.
    1. Cingolani P, Platts A, Wang LL, Coon M, Nguyen T, Wang L, Land SJ, Lu X, Ruden DM, et al. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso‐2; iso‐3. Fly. 2012;6:80–92. doi: 10.4161/fly.19695
    1. Liu X, Wu C, Li C, Boerwinkle E. dbNSFP v3. 0: a one‐stop database of functional predictions and annotations for human nonsynonymous and splice‐site SNVs. Hum Mutat. 2016;37:235–241. doi: 10.1002/humu.22932
    1. Landrum MJ, Lee JM, Benson M, Brown GR, Chao C, Chitipiralla S, Gu B, Hart J, Hoffman D, Jang W, et al. ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 2018;46:D1062–D1067. doi: 10.1093/nar/gkx1153
    1. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier‐Foster J, Grody WW, Hegde M, Lyon E, Spector E, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. J Mol Diagn. 2015;17:405–423. doi: 10.1038/gim.2015.30
    1. Ellard SBE, Callaway A, Berry I, Forrester N, Turnbull C, et al. ACGS Best Practice Guidelines for Variant Classification in Rare Disease 2020. Association for Clinical Genomic Science. ACGS Guidelines; 2020.
    1. Muiño‐Mosquera L, Steijns F, Audenaert T, Meerschaut I, De Paepe A, Steyaert W, Symoens S, Coucke P, Callewaert B, Renard M, et al. Tailoring the American College of Medical Genetics and Genomics and the Association for Molecular Pathology Guidelines for the Interpretation of Sequenced Variants in the FBN1 Gene for Marfan Syndrome: proposal for a disease‐and gene‐specific guideline. Circ Genom Precis Med. 2018;11:e002039. doi: 10.1161/CIRCGEN.117.002039
    1. Wickham HFR. ggplot2: elegant graphics for data analysis. Available at: Accessed September 20, 2021.
    1. Wickham HFR, Henry L & Muller KJ. dplyr: a fast, consistent tool for working with data frame like objects, both in memory and out of memory. Available at: . Accessed September 20, 2021.
    1. Signorell AAK, Alfons A, Anderegg N, Aragon T & DescTools AA. Tools for descriptive statistics. Available at: . Accessed September 20, 2021.
    1. Team RC . R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing. Available at: . Accessed September 20, 2021.
    1. England N . National Genomic Test Directory.
    1. Pliskin JS, Shepard DS, Weinstein MC. Utility functions for life years and health status. Oper Res. 1980;28:206–224. doi: 10.1287/opre.28.1.206
    1. Weerakkody R, Ross D, Parry DA, Ziganshin B, Vandrovcova J, Gampawar P, Abdullah A, Biggs J, Dumfarth J, Ibrahim Y, et al. Targeted genetic analysis in a large cohort of familial and sporadic cases of aneurysm or dissection of the thoracic aorta. Genet Med. 2018;20:1414–1422. doi: 10.1038/gim.2018.27

Source: PubMed

3
Subscribe